Clinical utility of whole-genome DNA methylation profiling as a primary molecular diagnostic assay for central nervous system tumors—A prospective study and guidelines for clinical testing
暂无分享,去创建一个
Mahlon D. Johnson | M. Rosenblum | P. Canoll | J. Golfinos | Q. Mao | J. Wisoff | M. Snuderl | A. Tsirigos | D. Orringer | C. Horbinski | D. Boue | Seema Patel | D. Zagzag | D. Mcguone | D. Pisapia | Mandisa Wen | Ivy Tran | J. Serrano | M. Karajannis | D. Placantonakis | Joseph Fullmer | E. Sulman | B. Mobley | N. Tsankova | L. Parsons | S. Gardner | D. Harter | J. DeWitt | Christian J. Davidson | M. Umphlett | Amanda M. Hopp | J. Jarzembowski | A. Faustin | M. Gokden | A. Segura | M. Suchi | Sylvia C. Kurz | G. Shen | M. Barbaro | Kristyn Galbraith | Christine Cordova | D. Pacione | S. Shroff | Timothy E. Richardson | C. Sen | Eveline Teresa Hidalgo | E. Maloku | B. Liechty | Misha Movahed-Ezazi | O. Krasnozhen-Ratush | Steven A. Drexler | Wesley R. Samore | P. Gopal | Nitin R. Wadhwani | Paula N. North | Christopher M William | J. Allen | Varshini Vasudevaraja | Nancy Abdallat | Marissa Spino-Keeton | Leah Geiser Roberts | Midhat S Farooqui
[1] E. Ruppin,et al. Impact of the methylation classifier and ancillary methods on CNS tumor diagnostics. , 2021, Neuro-oncology.
[2] Lydia Y. Liu,et al. A clinically applicable integrative molecular classification of meningiomas , 2021, Nature.
[3] A. Jemal,et al. Brain and other central nervous system tumor statistics, 2021 , 2021, CA: a cancer journal for clinicians.
[4] Jennie W. Taylor,et al. Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas. , 2021, Neuro-oncology.
[5] A. Heguy,et al. Genome-Wide DNA Methylation Profiles in Community Members Exposed to the World Trade Center Disaster , 2020, International journal of environmental research and public health.
[6] Mariella G. Filbin,et al. Molecular and clinicopathologic features of gliomas harboring NTRK fusions , 2020, Acta Neuropathologica Communications.
[7] M. Snuderl,et al. Methylation Profiling of Medulloblastoma in a Clinical Setting Permits Sub-classification and Reveals New Outcome Predictions , 2020, Frontiers in Neurology.
[8] M. Snuderl,et al. Feasibility and clinical utility of a pan-solid tumor targeted RNA fusion panel: A single center experience. , 2020, Experimental and molecular pathology.
[9] C. Ida,et al. Frequency of false-positive FISH 1p/19q codeletion in adult diffuse astrocytic gliomas , 2020, Neuro-oncology advances.
[10] M. Kool,et al. Diffuse glioneuronal tumour with oligodendroglioma‐like features and nuclear clusters (DGONC) – a molecularly defined glioneuronal CNS tumour class displaying recurrent monosomy 14 , 2019, Neuropathology and applied neurobiology.
[11] M. Snuderl,et al. GOPC-ROS1 Fusion Due to Microdeletion at 6q22 Is an Oncogenic Driver in a Subset of Pediatric Gliomas and Glioneuronal Tumors. , 2019, Journal of neuropathology and experimental neurology.
[12] P. Delgado-López,et al. Central nervous system ependymoma: clinical implications of the new molecular classification, treatment guidelines and controversial issues , 2019, Clinical and Translational Oncology.
[13] David T. W. Jones,et al. Extensive Molecular and Clinical Heterogeneity in Patients With Histologically Diagnosed CNS-PNET Treated as a Single Entity: A Report From the Children's Oncology Group Randomized ACNS0332 Trial. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] G. Reifenberger,et al. DNA methylation-based classification of ependymomas in adulthood: implications for diagnosis and treatment , 2018, Neuro-oncology.
[15] Martin Sill,et al. Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience , 2018, Acta Neuropathologica.
[16] David T. W. Jones,et al. Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations , 2018, Acta Neuropathologica.
[17] David T. W. Jones,et al. DNA methylation-based classification of central nervous system tumours , 2018, Nature.
[18] Martin Sill,et al. DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. , 2017, The Lancet. Oncology.
[19] Roland Eils,et al. New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs , 2016, Cell.
[20] Susan M. Chang,et al. Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment , 2015, Acta Neuropathologica.
[21] S. Horvath. DNA methylation age of human tissues and cell types , 2013, Genome Biology.
[22] Paul A. Northcott,et al. DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsies , 2013, Acta Neuropathologica.
[23] David T. W. Jones,et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. , 2012, Cancer cell.
[24] M. J. van den Bent. Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician’s perspective , 2010, Acta neuropathologica.
[25] G. Barger,et al. Discrepancies in diagnoses of neuroepithelial neoplasms , 2000, Cancer.
[26] M. Snuderl,et al. Whole Genome DNA Methylation Analysis of Human Glioblastoma Using Illumina BeadArrays. , 2018, Methods in molecular biology.